期刊文献+

PD-1靶向性肿瘤治疗抗体药物在消化道肿瘤中的应用价值 被引量:3

The Application Value of PD-1 Targeted Tumor Therapy Antibody Drugs in Digestive Tract Tumors
下载PDF
导出
摘要 目的探讨PD-1靶向性肿瘤治疗抗体药物在消化道肿瘤中的应用价值。方法采用随机、对照与双盲研究方法,选择食管癌晚期患者116例作为本次研究的对象,根据随机数字表法原则分为观察组与对照组,各58例。对照组给予常规化疗,观察组在对照组治疗的基础上给予PD-1靶向治疗,2组都治疗观察4个周期。结果观察组与对照组的总有效率为65.5%和48.3%,差异有统计学意义(P<0.05)。2组均有不同程度的不良反应,主要以心脏毒性、胃肠道反应、皮疹、白细胞减少等为主,但差异无统计学意义(P>0.05)。治疗后观察组的社会关系、环境、生理、心理等领域评分都明显高于对照组(P<0.05)。随访至今,观察组与对照组中位总生存期为25月(18~32月)、33月(27~40月),观察组长于对照组(log-rankχ~2=32.426,P<0.05)。结论 PD-1靶向性肿瘤治疗抗体药物在食管癌中的应用能提高治疗效果,且不增加不良反应,可延长患者的生存时间,改善患者的生活质量。 Objective To investigate the application value of PD-1 targeted tumor therapy antibody drugs in digestive tract tumors. Methods Used a randomized,controlled and double-blind study method,A total of 116 patients with advanced esophageal cancer were selected as the subjects of this study,all the cases were randomly divided into the observation group and the control group with 58 cases in each group,the control group was given conventional treatment,the observation group was given the PD-1 targeted therapy based on the control group,both groups were observed 4 cycles of treatment. Results The total effective rate of the observation group and the control group was 65. 5% and 48. 3%,and the difference was statistically significant( P 〈0. 05). There were different degrees of adverse reactions,mainly cardiac toxicity,gastrointestinal reactions,skin rash,white blood cell reduction and so on in the 2 groups,there was no significant difference compared between the 2 groups( P 〉 0. 05). After treatment,the scores of social relations,environment,physiology and psychology in the observation group were significantly higher than those of the control group( P 〈 0. 05). The median survival time of the observation group and the control group was 25 months( 18 ~ 32 months) and 33 months( 27 ~ 40 months). The observation group was longer than the control group( log-rankχ~2= 32. 426,P 〈 0. 05). Conclusion The application of PD-1 targeted tumor therapy antibody drugs in esophageal cancer can improve the treatment effect,and it does not increase the adverse reaction,it can prolong the survival time and improve the quality of life of patients.
作者 曹焱 潘慧丽 张超 CAO Yan;PAN Huili;ZHANG Chao(Aksu Region First People's Hospital in Xinjiang Uygur Autonomous Region,Aksu,84300)
出处 《实用癌症杂志》 2018年第8期1330-1332,共3页 The Practical Journal of Cancer
关键词 PD-1靶向性抗体 食管癌 不良反应 化疗 生活质量 PD-1 targeted antibodies Esophageal cancer Adverse reactions Chemotherapy Quality of life
  • 相关文献

参考文献5

二级参考文献8

共引文献21

同被引文献34

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部